IMS Reports 5% Growth in Retail Pharmacy Drug Sales for the 12 Months to April 2006   

IMS Health reported a 5% growth (at constant exchange) in drug sales to $371.27 billion through retail pharmacies in the 13 key markets in the 12 month period from April 2005 through to April 2006. 
  • The single largest therapeutic sub category in dollar sales continues to be the C10, hypolipidemia, class selling $29.09 billion with a growth of 6.9% in the 12 months to April 2006. The second biggest group is the A2, anti-ulcerants, class at $22.74 billion with a 2.9% growth. 
  • The best selling drug for the 12 months ending April 2006 was still Lipitor, worth over $11.43 billion, with a reduced growth at 4.9%. Nexium still has the largest growth at the top with 16.2%. The five top drugs are 1. Lipitor, 2. Nexium, 3. Plavix, 4. Zocor, 5. Seretide.
  • The top five corporations in the year to April 2006 are in order: 1. Pfizer, 2. GSK, 3. Norvartis, 4. Merck, 5. AstraZeneca.

Previous: « Week of July 3: Venture Capital Deal Flow - Search for the Next Big Thing

Next : » VC-Backed M&A Deals Continue to be More Dominant Over IPOs in Q2 2006


  ABOUT    CONTACT Metrics 2.0 RSS Feeds RSS   Metrics 2.0 Widgets for your site or blog WIDGETS   ARCHIVES


Enter Email for Daily Feed Delivery: